JNJ-80948543

Phase 1Small molecule

Johnson & Johnson

JNJ-80948543 is one of 100 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Leukemia, Myeloid, AcuteEnrolling by invitation

Lymphoma, Non-HodgkinActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Leukemia, Myeloid, AcutePhase 1

Enrolling by invitation

Lymphoma, Non-HodgkinPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Tafasitamab

Incyte

Preclinical

7 6

JNJ-80948543

Johnson & Johnson

Phase 1

4 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Lymphoma, Non-Hodgkin

NCT06139406

Q1 2027

Phase 1Active, not recruiting

Lymphoma, Non-Hodgkin

NCT06660563

Q3 2027

Phase 1Active, not recruiting

Lymphoma, Non-Hodgkin

NCT05424822

Clinical

Trials by Indication[1]

Lymphoma, Non-Hodgkin3 trials

A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05424822·167 enrolled

A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06660563·19 enrolled

A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06139406·70 enrolled

Leukemia, Myeloid, Acute1 trial

An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitation· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06788509·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for JNJ-80948543. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-80948543 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-80948543. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-80948543

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Lymphoma, Non-Hodgkin3 trials

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News